Cooperative Group /JCOG. Multi-modality therapy. Cooperative Group. adjuvant therapy. Chemoradiation % % 7.5% 7.2% 7.0% 2.5% 2.1% 19.
|
|
- Agatha Owens
- 5 years ago
- Views:
Transcription
1 Cooperative Group 5. /JCOG 1. Multi-modality therapy Cooperative Group 5. adjuvant therapy Chemoradiation 2000 : , 2.5% 2.1% 3.1% 3.2% 4.2% 4.3% 6.4% 6.8% 6.9% % 8.3% 8.0% 7.7% 7.5% 7.2% 7.0% /22.4% % % 3.6% 3.7% 3.8% 3.9% 4.6% 5.8% % % % % 8.5%
2 2001 / % 7.3% 32.4% 33.4% Registration trial IND (Investigational New Drug) trial Industry-sponsored trial Investigator-initiated trial RCT 1 / /
3 NCIC MRC 1950 EORTC SWOG CALGB ECOG 1962 NSABP NCCTG RTOG GOG COG ACOSOG Cooperative Group WJTOG JFMC NSAS JCOG Cooperative Group 5. 60% Cooperative Group ASCO plenary session 6 Cooperative Group Patient-reported outcome: PRO / 4. Cooperative Group 5. / etc. central, site-visit 3. Phase I Phase II Phase III true surrogate Phase II Phase III Benefit Phase II / Risk / Quality of Life QOL MTDDLT Endpoint surrogate endpoint true endpoint /stage / HbA1c rationale
4 sample size JCOG9511 Scandinavian Simvastatin Survival Study (4S) or 70 Lancet 344, N Engl J Med CASE-J Candesartan Antihypertensive Survival Evaluation in Japan 23 (1) mmHg70y:160mmHgor 90mmHg 1 180mmHg or 110mmHg II FBS126mg/dl, BS200mg/dl,, TIA or Cr1.3mg/dl II vs. TIA etc. 40% 3200 ACE Ca FDA Cooperative Group etc vs. 5. A B 3 Essential Components / Data & Safety Monitoring Investigators Data Coordinating Center Data coordinating center Treatment coordinating center Central Labo. Reading Center ECG
5 Cooperative Group Statistical/Data Center MD Operations Office/Center MD Data & Safety Monitoring 1 10 Central Labo MD Protocol Review Group Chair RCT streptomycin vs RCT NCI - Dr. Gordon Zubrod RCT 6-mercaptopurine, methotrexate Acute Leukemia Group A, B 1976 Cancer and Leukemia Group B CALGB Zubrod Eastern Solid Tumor Group 1956 RCT Eastern Cooperative Oncology GroupECOG Southwest Cancer Chemotherapy Study Group (SWCCSG) 1973 The Southwest Oncology GroupSWOG 1955 NCI Clinical Studies Panel 1958 RCT Cooperative groups Clinical Trials Cooperative Group Program NCI 500$ $ NCI-sponsored Cooperative Groups NCI DHHS Department of Health & Human Services OHRP Office for Human Research Protection Adult, multi-modality ( Big 4 ) ACF AOA AHCPR CDC FDA HCFA HRSA IHS PSC SAMHSA NIH Health Care Cancer and Leukemia Group B (CALGB) Food & Drug Financing National Institute Administration Administration of Health Clinical center Eastern Cooperative Oncology Group (ECOG) NEI NHLBI NHGRI NIA NIAAA NIAID NNIAMS NICHD NIDCD NIDCRNIDDKD NIDA NIEHS North Central Cancer Treatment Group (NCCTG) NIGMS NIMHNINDSNINR NLM NCI CC CIT NCCAM NCRR FIC CSR National Cancer Institute Southwest Oncology Group (SWOG) 4000 full time2000 NCI-Frederick IND Disease-oriented DCTD Division of Cancer Treatment and Diagnosis DCP Division of National Surgical Adjuvant Breast and Bowel Project DTP CTEP CTC(AE) Cancer Prevention Cancer Therapy (NSABP) Discovery, screening, Evaluation Program manufacturing Research Bases Gynecologic Oncology Group (GOG) CCOP: 50 Community Clinical Specific types SWOG NSABP ECOG Oncology Program Univ. Jonsson Wisconsin Kimmel Kaplan Yale Univ. Fred Hutchinson Duke Univ. RTOG CALGB GOG American College of Surgeons Oncology Group (ACOSOG) Roswell Park Dana-Farber MD Anderson Radiation Therapy Oncology Group (RTOG) Fox Chase Johns Hopkins Epply NCCTG COG ACOSOG CRC NCI-sponsored NCI-sponsored Community Children s Oncology Group (COG) Cancer Center : 60 Cooperative Group : 9 Hospitals translational - phase I - phase II phase II - III, prevention /Oncologists
6 1 NCI NCI Clinical Trials Cooperative Group Program / Cancer Center Program 1963 P30 Cancer Center Support Grant FDA IND application phase Iphase II NCI 2 /1 3 phase III Taxol CRC 3. Cooperative groups NCI-CTEP Community Clinical Oncology ProgramCCOP 1983 NCI 50 CCOPs 13 Minority CCOP CRC NCI-CTEP 3 Cooperative groups Community hospitals NCI-DCP CCOPCommunity Clinical Oncology Program Cooperative Group phase II phase III Multi-modality Group NIH FDA / Disease-specific Group Multi-disease Group JCOG vs 2000 Cancer Cooperative Groups WJTOG ( ) -NPO - JMTO (multi-disease) -NPO NSAS/CSPOR ( ) JFMC (multi-disease) - - Cooperative Group JCOG (multi-disease) NPO - QA + QC Cooperative Group Sponsor investigator ICH-GCP sponsor-investigator
7 Cooperative Group SWOG ? Phase III HQ 85 Multi-disease group EORTC JCOG Disease-oriented NSABP NSAS ? Cooperative Group NPO or multi-disease group CRFCase Report Form Phase II phase III Phase Iphase I/II Cancer Centers EORTC sponsor Cooperative group NCI FDA NCI Multi-disease vs. Disease-specific Cooperative Group Multi-disease Disease-specific Cooperative Group Group Group / Pros. peer review Cooperative Group Cons. NSABPSWOG SWOGNSABP JCOG Cooperative Group Cooperative Group Cooperative Group CRCDMSoCRA CTC(AE) / RECIST Pros Cons Cooperative Group Case Report Form QA NCI
National Cancer Institute Clinical Trial Cooperative Groups
National Cancer Institute Clinical Trial Cooperative Groups Perspectives from the National Surgical Adjuvant Breast and Bowel Project Joyce Mull, MPM Director, Regulatory Affairs NSABP Foundation, Inc.
More informationNCCN National Comprehensive Cancer Network Directory Information
Please provide the information requested below. The information contained herein is for NCCN purposes only and will not be published without your express written consent below. Name: Last First Middle
More informationRECENT TRENDS. The Impact of the NCI and NIBIB
The Impact of the NCI and NIBIB James Deye, Ph.D. Program Director on Medical Physics RECENT TRENDS doubling of the NIH budget over last 5 years; appointment of new heads of NIH and NCI; creation of NIBIB;
More informationBD-STEP: Tackling Key Issues Across Cancer Research and Care
BD-STEP: Tackling Key Issues Across Cancer Research and Care Michelle Berny-Lang, Ph.D. Program Director Center for Strategic Scientific Initiatives Office of the Director, National Cancer Institute BD-STEP
More informationNIDDK: Priorities and Perspectives. NIDDK: Support of Fatty Liver Disease Research. National Institutes of Health $30,142,653,000
NIDDK: Priorities and Perspectives Edward Doo Program Director Liver Diseases Research Branch, NIDDK National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health STOPNASH
More informationDr. Sause: Clinical, Research, and Administration. Vilija N. Avizonis, MD Radiation Oncologist; Intermountain Medical Center; Murray, Utah
Dr. Sause: Clinical, Research, and Administration Vilija N. Avizonis, MD Radiation Oncologist; Intermountain Medical Center; Murray, Utah Objectives: Identify Dr. Sause's educational achievements Discuss
More information8/17/2011. FY 2010 President s Budget Request Total NIH Budget Authority $31.0 Billion
NIH OD NCI NEI NHLBI NHGRI NIA NIAAA NIAID NIAMS NIBIB NICHD NIDCD NIDCR NIDDK NIDA NIEHS NIGMS NIMH NINDS NINR NLM CIT CSR FIC NCCAM NCMHD NCRR FY 2010 President s Budget Request Total NIH Budget Authority
More informationPlanning, Priority Setting, and Budget Development for NIH AIDS Research
Planning, Priority Setting, and Budget Development for NIH AIDS Research Robert W. Eisinger, Ph.D. Office of AIDS Research s of Health Focus of Presentation Overview of OAR Priority Setting Process Budget
More informationPresident's FY 2009 Budget Request for R&D and Public Health Programs
Request for R&D and Public Health Programs (in millions) : http://www.whitehouse.gov/omb/budget/fy2007/ FY Final Appropriations: http://thomas.loc.gov/home/approp/app08.html FY Levels based on Documents
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationThank You. Presented By. Title Sponsor. Venue Host
Thank You Presented By Title Sponsor Venue Host NIDDK Research: Opportunities for Partnering Vladimir Knezevic, M.D. Senior Advisor for Commercial Evaluation, Technology Advancement Office, National Institute
More informationThe National Cancer Institute Community Oncology Research Program (NCORP) A Local Story
The National Cancer Institute Community Oncology Research Program (NCORP) A Local Story Connie Szczepanek RN, BSN Director Cancer Research Consortium of West Michigan (CRCWM NCORP) Page 1 of 37 1 Cancer
More informationIOM-ASCO Workshop. Cooperative Group Chairs Report. March 21, Jan Buckner, MD. Mayo Clinic Rochester, MN
IOM-ASCO Workshop March 21, 2011 Cooperative Group Chairs Report Jan Buckner, MD Mayo Clinic Rochester, MN Therapeutic Advances Cooperative Groups have been successfully collaborating to conduct high-quality
More informationThe NIH SBIR/STTR Program & Universities
The NIH SBIR/STTR Program & Universities SBIR/STTR & Commercialization of University Innovations February 5, 2014 Matthew Portnoy, Ph.D. SBIR/STTR Program Coordinator, NIH 1 Topics Size of NIH/HHS program
More informationFogarty Initiatives for Building Capacity in HIV/AIDS
Fogarty Initiatives for Building Capacity in HIV/AIDS April 13, 2010 Michael P. Johnson, M.D., M.P.H Deputy Director Fogarty International Center Global Health Transition in 21 st Century the unfinished
More informationThe Clinical Research E-News
Volume 3: ISSUE 11: June 15, 2011 The Clinical Research E-News Reminder: CRA Quarterly Meeting, Philadelphia, PA: 10-11am on Wednesday June 22nd- Virtual Meeting: dial information attached in a separate
More informationNational Cancer Policy Forum Workshop on Multi-Center Phase 3 Clinical Trials and NCI Cooperative Groups
National Cancer Policy Forum Workshop on Multi-Center Phase 3 Clinical Trials and NCI Cooperative Groups Session 3: Data Collection Standards to Establish Safety and Efficacy: How Much Data Is Enough?
More informationThe Clinical Research E-News
Volume 3: ISSUE 8: May 5, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: E2906, Phase III randomized
More informationSession II: Academic Research in Breast Cancer: Challenges and Opportunities Robert L. Comis, MD ECOG-ACRIN Group Co-Chair
Session II: Academic Research in Breast Cancer: Challenges and Opportunities Robert L. Comis, MD ECOG-ACRIN Group Co-Chair Symposium: Innovation in Breast Cancer 2014 Madrid, Spain February 21, 2014 Cancer
More informationHandbook of Human Tissue Sources
ABBREVIATIONS ACTG ADA AFDIL AFIP AIDS ALL AMB AM-CTC AML ARC ARNC ART ASCO BBDR BTR CALGB CAP CBCTR CCCBB CCG CCOP CDC cdna AIDS Clinical Trials Group American Diabetes Association Armed Forces DNA Identification
More informationDiversity Clinical Research Workshop Invited Faculty
Diversity Clinical Research Workshop Invited Faculty Alex A. Adjei, MD, PhD, FACP Professor and Chair, Department of Medicine Senior Vice President of Clinical Research The Katherine Anne Gioia Chair in
More informationRare Cancers: The added value of closer cooperation
Rare Cancers: The added value of closer cooperation Denis Lacombe Director EORTC Headquarters Brussels, Belgium Plan About EORTC Some specifics to be highlighted Examples of different models Global European
More informationFY 2008 Appropriations for R&D and Public Health Programs (in millions)
FY 2008 Appropriations for R&D and Public Health Programs (in millions) AGENCY PROGRAM FY 2008 Appropriations Status: http://thomas.loc.gov/home/approp/app08.html FY 2008 : http://www.whitehouse.gov/omb/budget/fy2007/
More informationThe RPC s Evaluation of Advanced Technologies. AAPM Refresher Course July 29, 2008 Geoffrey S. Ibbott, Ph.D. and RPC Staff
The RPC s Evaluation of Advanced Technologies AAPM Refresher Course July 29, 2008 Geoffrey S. Ibbott, Ph.D. and RPC Staff 1 http://rpc.mdanderson.org Supported by: NCI grants CA10953 and CA81647, and an
More informationThe NIH STTR Program
The NIH STTR Program May 1, 2015 Matthew Portnoy, Ph.D. SBIR/STTR Program Coordinator, NIH 1 Topics Size of NIH/HHS program Set-asides & spending Research Institutions and Universities in STTR Discretionary
More informationAdvancing Therapeutic Development for Pain and Opioid Use Disorder through Public-Private Partnerships
The National Academies of SCIENCES ENGINEERING MEDICINE Advancing Therapeutic Development for Pain and Opioid Use Disorder through Public-Private Partnerships Leadership The NIH Pain Consortium Mission
More informationAlliance Organizational Structure. Trini Ajazi, MM Alliance Chief Administrative Officer Clinical Research Professional Orientation
Alliance Organizational Structure Trini Ajazi, MM Alliance Chief Administrative Officer Clinical Research Professional Orientation May 10, 2017 NCI-NCTN National Cancer Institute (NCI) National Clinical
More informationEASTERN COOPERATIVE ONCOLOGY GROUP
EASTERN COOPERATIVE ONCOLOGY GROUP E5204 INTERGROUP RANDOMIZED PHASE III STUDY OF POSTOPERATIVE OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN VS OXALIPLATIN, 5-FLUOROURACIL, LEUCOV- ORIN AND BEVACIZUMAB FOR
More informationChanging the Clinical Trials System: An NCI Update. Michigan Cancer Consortium Annual Meeting November 5, Marge Good, RN, MPH, OCN
Changing the Clinical Trials System: An NCI Update Marge Good, RN, MPH, OCN Michigan Cancer Consortium Annual Meeting November 5, 2014 These slides are the property of the presenter. Do not reproduce without
More informationOverview of the NIH. National Institutes of Health (NIH)
Overview of the National Institutes of Health (NIH) October 16, 2008 Craig Formby, Ph.D. Distinguished Graduate Research Professor Colleges of Arts & Sciences, Medicine, and Engineering Director, Office
More informationNeuro-Oncology Program
Neuro-Oncology Program The goals of the Neuro-oncology Committee are: 1) to improve duration and quality of life of brain tumor patients; 2) to assess disease and treatment-related effects on neurocognitive
More informationPhysical activity, Obesity, Diet and Colorectal Cancer Prognosis. Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA
Physical activity, Obesity, Diet and Colorectal Cancer Prognosis Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA Colorectal Cancer Incidence ~148,000 cases in US annually and ~50,000
More informationOBTAINING A MENTORED CAREER DEVELOPMENT AWARD: PERSPECTIVES OF A MENTOR, APPLICANT AND REVIEWER
OBTAINING A MENTORED CAREER DEVELOPMENT AWARD: PERSPECTIVES OF A MENTOR, APPLICANT AND REVIEWER May 15, Friday 4pm BRIEF AGENDA 1) Carol Mangione, MD MSPH- Introduction 2) Richard Kravitz, MD MSPH- Perspective
More informationJanuary Schema: S T R A T I F Y. Age 1. <50 2. >50
January 2004 9813-1 RTOG Protocol No: 9813 Protocol Status: ECOG Protocol No: R9813 Phase I: Opened June 16, 2000 NCCTG Protocol No: R9813 Closed January 25, 2002 SWOG Protocol No: R9813 Phase III: Opened
More informationCON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer
CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute Emory University
More informationADC Clinical Core Leaders meeting: Can we do more with biomarkers? Joseph Quinn, MD. April 16, 2016
ADC Clinical Core Leaders meeting: Can we do more with biomarkers? Joseph Quinn, MD April 16, 2016 1 New initiatives with biomarkers of neurodegenerative disease: Extracellular micrornas as biomarkers
More informationWhat Can Go Wrong in Radiation Treatment: Data from the RPC. Geoffrey S. Ibbott, Ph.D. and RPC Staff
What Can Go Wrong in Radiation Treatment: Data from the RPC Geoffrey S. Ibbott, Ph.D. and RPC Staff Clinical NCI Trials CALGB 1768 Participating Institutions NCCTG ECOG COG ACOSOG SWOG QARC RPC ATC RTOG
More informationLeveraging Innovation to Design Future Clinical Trials. Outline. Multi-Institutional Research 7/15/2015
Leveraging Innovation to Design Future Clinical Trials Jeff M. Michalski, MD, MBA, FACR, FASTRO The Carlos A Perez Distinguished Professor of Radiation Oncology Outline National Clinical Trial Network
More informationCCG-3891 LONG TERM OUTCOME FOR CHILDREN WITH HIGH RISK NEUROBLASTOMA Additional Information on Corrected Overall Survival Results April 10, 2014
Group Chair Peter C. Adamson, M.D. adamson@email.chop.edu Group Vice Chair Susan Blaney, M.D. smblaney@txch.org Chief Operating Officer Elizabeth O Connor, M.P.H. econnor@childrensoncology group.org Chief
More informationAmerican College of Surgeons Clinical Research Program Surgical Investigators Webinar. October 5, Moderator: Y. Nancy You, M.D.
American College of Surgeons Clinical Research Program Kelly K. Hunt, M.D. Program Director American College of Surgeons Clinical Research Program Surgical Investigators Webinar October 5, 2018 Moderator:
More informationComposed of 27 Institutes and Centers.
October 7, 2009 John C. Higginbotham, PhD, MPH Associate Dean for Research & Health Policy Professor and Chair, Department of Community & Rural Medicine Director, Rural Health Institute for Clinical &
More informationAmerican College of Surgeons Clinical Research Program Surgical Investigators Webinar. November 17, Moderator: Y. Nancy You, M.D.
American College of Surgeons Clinical Research Program Kelly K. Hunt, M.D. Program Director American College of Surgeons Clinical Research Program Surgical Investigators Webinar November 17, 2017 Moderator:
More informationStopping a cancer trial early: is it really for the benefit of patients? What about the quality of data?
Stopping a cancer trial early: is it really for the benefit of patients? What about the quality of data? Pinuccia Valagussa Fondazione Michelangelo, Milano I have no relevant relationships to disclose
More informationResearch Training Opportunities at the National Institute on Aging
Research Training Opportunities at the National Institute on Aging Arlene Jackson Jaron Lockett, Ph.D. NIA Intramural Scientific Recruiters NIA Recruitment 2010 National Institutes of Health (NIH) Mission:
More informationJefferson Kimmel Cancer Center Network Presents: The Clinical Research E-News. January 14, 2009
Jefferson Kimmel Cancer Center Network Presents: January 14, 2009 The Clinical Research E-News New Activations at TJU: NCCTG N0723: A Phase III Biomarker Validation Study of Second-Line Therapy in Patients
More informationNeuroscience International Funding Opportunities at NINDS & NIH
Neuroscience International Funding Opportunities at NINDS & NIH Yuan Liu, PhD Chief, Office of International Activities of Neurological Disorders & Stroke (NINDS) s of Health (NIH) U.S.A. July 20, 2007
More informationThe Clinical Research E-News
ISSUE 18: September 9, 2009 New Activations: The Clinical Research E-News SWOG0518, Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 2: ISSUE 19: October 13, 2010 Coming soon: RTOG 0929, A Randomized, Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant)
More informationThe Clinical Research E-News
Volume 3: ISSUE 5: March 23, 2011 The Clinical Research E-News Now Open: CALGB 90802, Randomized Phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal
More informationThe Thoracic Alliance for Cancer Trials. November 2016
The Thoracic Alliance for Cancer Trials November 2016 There is a significant unmet need in lung cancer research Lung cancer is both the most common cancer and the greatest cause of cancer death globally
More information/ NCCN. ACS (www.cancer.org) NCC (www.nccn.org) NCCN NCCN ACS ACS-2345
/2002 9 /2002 9 (NCCN) (ACS) NCCN ACS (www.cancer.org) NCC (www.nccn.org) NCCN 1-888-909-NCCN ACS 1-800-ACS-2345 NCCN ACS NCCN NCCN ACS NCCN 2002 (NCCN) (ACS) NCCN ACS ...................................
More informationThe GOG White Paper Revised March 4, 2011
The GOG White Paper Revised March 4, 2011 The purpose of this revised White Paper is to address the impact of the IOM Report on the GOG and to report the many accomplishments of the GOG. The major highlights
More informationTHE ROLE OF COOPERATIVE GROUPS IN CANCER CLINICAL TRIALS
Chapter 5 THE ROLE OF COOPERATIVE GROUPS IN CANCER CLINICAL TRIALS Ann M. Mauer, MD, Elizabeth S. Rich, MD, PhD and Richard L. Schilsky, MD Cancer and Leukemia Group B, Central Office of the Chairman,
More informationThe Clinical Research E-News
Volume 2: ISSUE 11: June 2, 2010 The Clinical Research E-News SPECIAL ALERT: The quarterly CRA Meeting will be held at 8:30am on June 16, 2010 at the Bluemle Science Building room 105. Now Open: SWOG0777,
More informationThe Clinical Research E-News
Volume 2: ISSUE 5: March 10, 2010 The Clinical Research E-News Coming soon: AZ1071, A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative
More informationThe Clinical Research E-News
Volume 3: ISSUE 9: May 18, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: RTOG 0837, A Randomized,
More informationProphylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer
Prophylactic Cranial Irradiation and Thoracic Radiotherapy in Extensive Stage Small-Cell Lung Cancer Dr Neil Bayman Consultant Clinical Oncology ESMO-Christie Preceptorship Programme in Lung Cancer, March
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationTrial record 1 of 1 for: GO28341 Previous Study Return to List Next Study
1 von 5 11.12.2013 09:04 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: GO28341 Previous Study Return to List Next Study A Study of GDC-0068 in Combination With Fluoropyrimidine
More informationThe Clinical Research E-News
Volume 2: ISSUE 6: March 24, 2010 The Clinical Research E-News SPECIAL ALERT: The annual JOG investigator Meeting will be held at 5pm on May 10, 2010 at the Loews Hotel. Now Open: AZ1071, A Phase II Study
More informationSUMMARY OF CHANGES Amendment 6, Version Date: March 29, 2010 [Broadcast: April 8, 2010]
Amendment 6, Version Date: March 29, 2010 [Broadcast: April 8, 2010] RTOG 0233, "A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation
More informationThe Clinical Research E-News
Volume 2: ISSUE 7: April 7, 2010 The Clinical Research E-News SPECIAL ALERT: The annual JOG investigator Meeting will be held at 5pm on May 10, 2010 at the Loews Hotel. Now Open: RTOG0831, A Randomized,
More informationCooperative Groups Session Transforming the NCI Clinical Trials System
Cooperative Groups Session Transforming the NCI Clinical Trials System Claudio Dansky Ullmann, M.D. Clinical Investigations Branch Cancer Therapy Evaluation Program National Cancer Institute 12 th International
More informationSlide 1. Slide 2. Slide 3. Reviews of NCI s Clinical Trials System. Cooperative Groups Session Transforming the NCI Clinical Trials System
Slide 1 Cooperative Groups Session Transforming the NCI Clinical Trials System Claudio Dansky Ullmann, M.D. Clinical Investigations Branch Cancer Therapy Evaluation Program National Cancer Institute 12
More informationNRG Publications Committee. Chair: Deborah Watkins Bruner, PhD Co-chairs: Elizabeth Gore, MD Thomas Julian, MD Krish Tewari, MD
NRG Publications Committee Chair: Deborah Watkins Bruner, PhD Co-chairs: Elizabeth Gore, MD Thomas Julian, MD Krish Tewari, MD NRG Abstract and Manuscript Submissions 161 Manuscripts 105 Publications in
More informationDietary Supplement Research Portfolio at the NIH, ,2
The Journal of Nutrition Commentary Dietary Supplement Research Portfolio at the NIH, 2009 2011 1,2 Mary L. Garcia-Cazarin, 3 * Edwina A. Wambogo, 3 Karen S. Regan, 3,4 and Cindy D. Davis 3 3 Office of
More informationhttps://clinicaltrials.gov/ct2/show/nct ?term=inge-b&rank=1
Seite 1 von 6 A service of the U.S. National Institutes of Health Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting Trial record 1 of 1 for: INGE-B Previous Study Return
More informationProstate Cancer Clinical Trials - PHEN s Rally Update and Next Steps
Prostate Cancer Clinical Trials - PHEN s Rally Update and Next Steps 13 th Annual African- American Prostate Cancer Disparity Summit PHEN: Prostate Health Educa?on Network Bernard W. Parker MD, FACP CAPT,
More informationClinical Research in Rare Cancers. Friday 10 th February Matt Seymour & Nicola Keat
Clinical Research in Rare Cancers Friday 10 th February 2012 Matt Seymour & Nicola Keat Rare cancer is a common disease Rare Cancer : [prevalence
More informationCurrent Status of Adjuvant Therapy for Colorectal Cancer
Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas
More informationFDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE NODE-POSITIVE BREAST CANCER
NEWS RELEASE Media Contact: Kimberly Ocampo (650) 467-0679 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Ajanta Horan (650) 467-1741 FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF
More informationComparative Effectiveness Research in Cancer: Robert T. Croyle, Ph.D. y, National Cancer Institute October 2010
Comparative Effectiveness Research in Cancer: Past, Present and Future Robert T. Croyle, Ph.D. y, National Cancer Institute October 2010 Presentation Overview Past Clinical trials system and population
More informationThe Clinical Research E-News
ISSUE 10: May 20, 2009 The Clinical Research E-News New Activations at TJU: No new activations. Regulatory Update: The following studies have had recent consent form changes posted on the repository website:
More informationHSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study A221101 ALLIANCE NCT01781468 Brain A Phase III Randomized, Double-Blind Placebo Controlled Study of
More informationThoracic Alliance for Cancer Trials. Overview and Membership April 2016
Thoracic Alliance for Cancer Trials Overview and Membership April 2016 There is a significant unmet need in lung cancer research Lung cancer is both the most common cancer and the greatest cause of cancer
More informationThe Clinical Research E-News
Volume 2: ISSUE 10: May 19, 2010 The Clinical Research E-News Coming soon: NSABP FC-6, A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mfolfox7 Plus Cetuximab
More informationSupplemental Table 1.1: Prostate cancer prognostic tools
Supplemental Table 1.1: Prostate cancer prognostic tools Features ANN^ BioChemical Capra^ CSQS EBRT Han Outcomes Cancer Specific - - +* + - - Non-Cancer Specific - - - + - - DFS/PFS +* +* +* - +* +* Clinical
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationAGENDA: FEBRUARY 22, 2018 INTRODUCTION
FDA-AACR-ASTRO Clinical Development of Drug-Radiotherapy Combinations Workshop with support from Cancer Research UK Combinations Alliance February 22-23, 2018 Bethesda, MD Purpose: There is great interest
More informationCCOP Clinical Trials Contributions and Challenges
CCOP Clinical Trials Contributions and Challenges Stephen S. Grubbs, M.D. Delaware Christiana Care CCOP Helen F. Graham Cancer Center National Cancer Policy Forum July 1, 2008 NCI Community Clinical Oncology
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 6: ISSUE 5: June 12, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationNational Cancer Institute
National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute Community Oncology Research Program (NCORP) Institute of Medicine Implementing
More informationPatient Reported Outcomes and Building a Career in Science
Patient Reported Outcomes and Building a Career in Science Deborah Watkins Bruner, RN, PhD, FAAN Robert W. Woodruff Professor of Nursing Director, Faculty Mentorship Nell Hodgson Woodruff School of Nursing
More informationVaccine Clinical. Cancer. Group. Working. Trial. Final Workshop, 10 November 2005
Cancer Vaccine Clinical Trial Working Group Final Workshop, 10 November 2005 CVCTWG Issues Cancer vaccines have unique developmental challenges. Some potential solutions exist. Not all potential solutions
More informationNCIC CTG Overview and Opportunities. Ralph Meyer Director, NCIC CTG
NCIC CTG Overview and Opportunities Ralph Meyer Director, NCIC CTG NCIC Clinical Trials Group A research organization A cooperative clinical trials group Previously funded by NCIC Now funded by CCSRI National
More informationLARGE TISSUE BANKS, REPOSITORIES, AND CORE FACILITIES
Chapter Three LARGE TISSUE BANKS, REPOSITORIES, AND CORE FACILITIES Large tissue banks and repositories exist in almost every sector of the scientific and medical communities, including the military, the
More informationSystems Biology and Mathematical Oncology at the National Cancer Institute
Systems Biology and Mathematical Oncology at the National Cancer Institute Shannon Hughes, Ph.D. Division of Cancer Biology 240-276-6180 shannon.hughes@nih.gov April 28, 2017 The National Institutes of
More informationNIDA/FDA Collaborations
NIDA/FDA Collaborations Wilson M. Compton, M.D., M.P.E. Director, Division of Epidemiology, Services and Prevention Research National Institute on Drug Abuse National Institutes of Health Tobacco use is
More informationSWOG Plenary I Translational Medicine Science as the Foundation for Rapid and Meaningful Advances in Oncology
SWOG Plenary I Translational Medicine Science as the Foundation for Rapid and Meaningful Advances in Oncology Lee M. Ellis, MD SWOG Vice Chair, Translational Medicine Departments of Surgical Oncology and
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationWhere We Are: NCI s Informed Consent Template and Updates to Address Changing Needs
Where We Are: NCI s Informed Consent Template and Updates to Address Changing Needs Andrea M. Denicoff, MS, RN Cancer Therapy Evaluation Program Division of Cancer Treatment & Diagnosis November 3, 2016
More informationThe Clinical Research E-News
Volume 2: ISSUE 8: April 21, 2010 The Clinical Research E-News SPECIAL ALERT: The annual JOG investigator Meeting will be held at 5:30pm on May 10, 2010 at the Loews Hotel. Coming soon: NSABP FC-6, A Phase
More information3.1.4 The phrase, and only focal nuclear, was clarified to and/or only focal nuclear.
For Protocol Amendment 3: RTOG 1221, Randomized Phase II Trial of Transoral Endoscopic Head And Neck Surgery followed by Risk-Based IMRT and Weekly Cisplatin versus IMRT and Weekly Cisplatin for HPV Negative
More informationChildren s Oncology Group: What We Learned In The Merger Process
: What We Learned In The Merger Process Gregory H. Reaman, MD Professor of Pediatrics The George Washington University School of Medicine and Health Sciences PEDIATRIC ONCOLOGY GROUP Children s Oncology
More informationBrain tumor clinical trials: a surgeon s perspective
Brain tumor clinical trials: a surgeon s perspective Fred G. Barker II, MD Penn Brain Tumor Academy May 13, 2016 No financial conflicts Non-FDA-approved drug uses will be discussed Brain tumor clinical
More informationThe Clinical Research E-News
Volume 3: ISSUE 3: February 16, 2011 The Clinical Research E-News Now Open: RTOG 0631, Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis RTOG 1010, A Phase III Trial Evaluating
More informationCancer research and cooperative groups: LACOG experience. Gustavo Werutsky LACOG Scientific Director
Cancer research and cooperative groups: LACOG experience Gustavo Werutsky LACOG Scientific Director Globalization of Clinical Research Clinical Studies Outside USA rug Information Association www.diahome.org
More information